

## Confirmed Speakers

### Invited Lectures

#### Fragment Based Drug Discovery of Selective Inhibitors of Fibroblast Growth Factor Receptors



Dr Patrick ANGIBAUD  
(JANSSEN R&D, Val de Reuil, France)

#### Chemoinformatics-Driven View of Kinase Drug Discovery (Lecture sponsored by ChemMedChem)



Prof. Jürgen BAJORATH  
(UNIVERSITY OF BONN, Bonn, Germany)

#### Kinase Inhibitors for Non-oncological Indications: Is there a Future ?



Dr Dorian FABBRO  
(PIQUR THERAPEUTICS, arlesheim, Switzerland)

#### CDK8 Inhibitors with Pre-Engineered Long Residence Time: From Design to Tumor Xenograft Models



Dr Koen HEKKING  
(MERCACHEM-SYNCOM, Nijmegen, The Netherlands)

#### Lead Optimization as a Playground for New Concepts, Reactions and Chemical Modalities: Development of Several Generations of Clinical CDK Inhibitors at Bayer AG



Dr Ulrich LÜCKING  
(BAYER HEALTHCARE, Basel, Switzerland)

#### Discovery, Development and In Vivo Profiling of a Novel Class of Immunosuppressive PI4KIII? Lipid Kinase Inhibitors



Dr James REUBERSON  
(UCB, Slough, United Kingdom)

### Oral Communications

#### OC02 - Discovery And Development Of Highly Potent And Selective FLT3 Kinase Inhibitors, A New Class of Peripheral Drugs for Treating Neuropathic Pain



Dr Claire AMIABLE  
(BCI PHARMA, Montpellier, France)

#### OC01 - A Fast in Silico Fragment-Based Design Tool for the Discovery of Novel Kinase Inhibitors



Prof. Pascal BONNET  
(UNIVERSITY OF ORLÉANS, Orléans, France)

## Confirmed Speakers

---

### OC03 - Imidazo[4,5-B]Pyridine Derivatives as Potent Tam Inhibitors: From Synthesis To Cellular Imaging



Dr Sandrine PIGUEL  
(UNIVERSITY PARIS-SACLAY, Orsay, France)